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Abstract
Invasive candidiasis is a life-threatening infection in patients with haematological malignancies. The objective of our study was to determine
the incidence, microbiological characteristics and clinical outcome of candidaemia among hospitalized adult patients with haematological
malignancies. This is a population-based, prospective, multicentre study of patients ≥18 years admitted to haematology and/or
haematopoietic stem cell transplantation units of nine tertiary care Greek hospitals from January 2009 through to February 2012. Within
this cohort, we conducted a nested case-control study to determine the risk factors for candidaemia. Stepwise logistic regression was used
to identify independent predictors of 28-day mortality. Candidaemia was detected in 40 of 27 864 patients with haematological malignancies
vs. 967 of 1 158 018 non-haematology patients for an incidence of 1.4 cases/1000 admissions vs. 0.83/1000 respectively (p <0.001).
Candidaemia was caused predominantly (35/40, 87.5%) by non-Candida albicans species, particularly Candida parapsilosis (20/40, 50%). In vitro
resistance to at least one antifungal agent was observed in 27% of Candida isolates. Twenty-one patients (53%) developed breakthrough
candidaemia while receiving antifungal agents. Central venous catheters, hypogammaglobulinaemia and a high APACHE II score were
independent risk factors for the development of candidaemia. Crude mortality at day 28 was greater in those with candidaemia than in
control cases (18/40 (45%) vs. 9/80 (11%); p <0.0001). In conclusion, despite antifungal prophylaxis, candidaemia is a relatively frequent
infection associated with high mortality caused by non-C. albicans spp., especially C. parapsilosis. Central venous catheters and
hypogammaglobulinaemia are independent risk factors for candidaemia that provide potential targets for improving the outcome.
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Introduction
Invasive candidiasis is associated usually with excess morbidity
and mortality, longer hospital stays and higher hospital costs in
patients with haematological malignancies [1–5]. Candidaemia,
the most common form of invasive candidiasis, is associated
with unacceptably high mortality rates, reaching 40% among
haematology patients, despite the introduction of newer
antifungal agents [3]. Therefore, information on the incidence,
epidemiology, risk factors and outcome of this deadly infection
is of paramount importance in the care of patients with
haematological malignancies.
Most estimates of incidence and epidemiology of candida-
emia among patients with haematological malignancies have
been derived from studies conducted in single institutions or
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from retrospective surveys focusing on specific Candida
species. Thus, institution-specific limitations, such as local
epidemiology, patient populations, antineoplastic protocols,
available facilities, infection control policies, prophylaxis and
treatment practices, or even environmental exposures, pro-
hibit generalization of epidemiological findings across multiple
centres. Retrospective assessment of the incidence of candi-
daemia with use of microbiology or pharmacy databases and
discharge or death records has major limitations that could
lead to inaccurate estimates [6].
Prospective surveillance studies and/or nationwide regis-
tries of candidaemia and/or invasive fungal infections include
subpopulations of candidaemic haematology patients, providing
additional epidemiological information [7,8]. However, these
studies do not focus specifically on haematology patients with
candidaemia. Clinical trials and comparative studies on treat-
ment of candidaemia usually include only a paucity of
neutropenic patients with haematological malignancies.
The aim of our study, therefore, was to determine
prospectively the incidence, microbiological characteristics,
susceptibility patterns and clinical outcome of candidaemia
among hospitalized adult patients with haematological malig-
nancies. To that end, a prospective, multicentre, cohort study
was conducted in nine tertiary care Greek hospitals with
haematology and/or haematopoietic stem cell transplantation
(HSCT) units. Within this prospective cohort, we conducted a
nested case-control study to determine the risk factors for
candidaemia. Microbiology data on the distribution of Candida
species and their resistance patterns were also collected and
analysed. Finally, the epidemiology of candidaemia among
haematology patients was compared with that of non-haema-
tology patients admitted to the same hospitals during the study
period.
Design and Methods
Study population
We conducted a population-based, prospective, multicentre,
study of all patients ≥18 years of age admitted to haematology
and/or HSCT units of nine tertiary care Greek hospitals during
the period from 1 January 2009 through to 28 February 2012.
All patients admitted to the haematology units and to all other
non-haematology departments of the participating hospitals
were identified using both hospital and unit-specific databases.
Definition of case patients and selection of control patients
Candidaemia in a patient with haematological malignancy was
defined according to published guidelines [9]. Case patients
were identified by the primary physicians at the participating
haematology units. If multiple, distinct episodes of candidaemia
occurred in the same patient during the study period, then
only the first episode was included in our analysis.
Control patients were selected by the use of unit-specific
patient admission databases. In order to match control
patients to case patients with respect to time at risk of
developing candidaemia (i.e. length of stay in the same
haematology unit) we selected as control patients the two
subjects with haematological malignancies who were admitted
subsequent to the case of candidaemia and did not develop
candidaemia during their hospitalization. The index date was
considered as the day of positive blood culture for the case
patient and the corresponding day in the haematology unit for
the two matched controls. Candidaemia was defined by the
caring physician as catheter related: (i) when there was no
other apparent source of the infection; (ii) when the same
Candida species was isolated from both peripheral blood and
blood drawn from the lumen of the central venous catheter
(CVC) and/or from catheter-tip culture; and (iii) if the patient
had prolonged candidaemia that quickly resolved after remov-
ing the CVC. The CVC was considered to be removed if this
procedure was performed during the first 3 days following the
first blood culture positive for Candida infection. The terms of
de novo, breakthrough candidaemia, neutropenia and
Candida-related mortality were defined as described previously
[10].
Data collection
Data collection was performed by primary physicians at the
participating haematology units. On the index day, a standard-
ized form was used to record the following data: patient
demographics; type of underlying haematological malignancy;
history of prior chemotherapy and/or HSCT; depth of
neutropenia (absolute neutrophil count (ANC) <500, ANC
<100); duration of, and recovery from, neutropenia; presence
of CVC and subsequent removal; use of corticosteroids within
the previous 4 weeks; administration of total parenteral
nutrition; presence of diabetes mellitus or renal failure;
hypogammaglobulinaemia; use of growth factors; admission
to the intensive care unit (ICU); intercurrent bacterial
infection; and prior or concurrent use of antifungal agents
and/or broad spectrum antibiotics. The Acute Physiology and
Chronic Health Evaluation (APACHE II) score, Eastern Coop-
erative Oncology Group (ECOG) performance scale and
Glasgow Coma Scale (GCS) scores were calculated at the
onset of candidaemia.
The antifungal agents used for the treatment of candidaemia
were recorded, and the patientswere evaluated at days 7, 14 and
28 for evidence of disease, clinical and/or mycological response
and outcome. Cases of candidaemia in non-haematology
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patients of the participating hospitals, during the study period,
were identified through records of the microbiology laborato-
ries. Institutional review boards of all participating centres
approved the study protocol.
Microbiology studies
For case patients with candidaemia, information regarding
species of Candida was collected. Species identification was
performed in the microbiology laboratory of each participating
centre, by using standard methods. In order to eliminate
variation due to different techniques, methods and expertise
among the nine reporting microbiology laboratories, we
collected the available isolates (n = 30) after the conclusion
of the study and performed susceptibility testing in the same
laboratory by the same methods. Minimum inhibitory concen-
trations (MICs) were determined by using the most recent
interpretive breakpoints adopted by the Clinical and Labora-
tory Standards Institute (CLSI) and published in document
M27-S4 [11].
Statistical analysis
Categorical variables were compared using Fisher’s exact test
and continuous variables were compared using Student’s t-test
or the Mann–Whitney U-test. Survival was plotted by Kaplan–
Meier analysis and analysed by log-rank test. Logistic regres-
sion was used to identify variables independently associated
with the development of candidaemia. A separate logistic
regression model was used to identify the risk factors for
mortality. All variables associated with the outcome of
interest in the bivariate analysis (p <0.1) were included at
model entry, and a stepwise approach was used to identify
independent predictors of 30-day mortality. Variables were
retained in the final model if the p value was 0.05. All
calculations were performed with SPSS version 16 (SPSS,
Chicago, IL, USA).
Results
Incidence of candidaemia, demographics and clinical
characteristics of case patients and controls
During the study period, 27 864 adult patients with
haematological malignancy and 1 158 018 patients without
haematological malignancy were admitted to nine participat-
ing hospitals. A total of 40 haematology patients and 967
non-haematology patients were identified with candidaemia.
The incidence of candidaemia was 1.4 cases per 1000
admissions for patients with haematological malignancy vs.
0.83 cases per 1000 admissions in non-haematology patients
(p <0.001).
Risk factors for candidaemia among patients with
haematological malignancies
A total of 80 control patients were selected. Table 1 displays
clinical and demographic characteristics of candidaemia cases
and controls. On univariate analysis, case patients were more
likely than control patients to have a CVC in place, diabetes
mellitus, neutropenia, prior use of corticosteroids, hypo-
gammaglobulinaemia, history of HSCT and a higher APACHE II
score (Table 1). Multivariate analysis showed that CVC,
hypogammaglobulinaemia and an elevated APACHE II score
were independent risk factors for the development of
candidaemia (Table 1).
Distribution of Candida species and epidemiological
characteristics among patients with candidaemia
Most infections (35, 87.5%) were caused by non-Candida
albicans species. The distribution of Candida species in
decreasing order was Candida parapsilosis (20, 50%), Candida
tropicalis (6, 15%), C. albicans (5, 12.5%), Candida glabrata (4,
10%), Candida guilliermondii (2, 5%), and one each of other
species (Table 2).
Twenty-one patients (53%) developed breakthrough candi-
daemia, while receiving antifungal prophylaxis (9/21, 43%) or
empirical treatment (12/21, 57%). Prior antifungal exposure
included fluconazole (6/21, 29%), liposomal amphotericin B (5/
21, 24%), posaconazole (4/21, 19%) and echinocandin (2/21,
10%), while four patients received more than one antifungal
agent. The most common species recovered from break-
through cases was C. parapsilosis (62%). Twenty (50%) cases of
candidaemia were considered as CVC-related, with C. parapsi-
losis being the most common species recovered (55%).
Of the 967 episodes of candidaemia in non-haematology
patients, species identification was performed in 752 isolates.
The most frequently reported species were C. albicans (392/
752, 52%), C. parapsilosis (275/752, 36.5%) and C. tropicalis (85/
752, 11.3%).
Non-C. albicans candidaemia was significantly more frequent
among haematology patients (35/40, 87%) compared with
non-haematology patients (360/752, 48%) (p <0.0001). Candi-
daemia caused by C. parapsilosis also occurred more frequently
in patients with haematological malignancies (20/40, 50%) than
in non-haematology patients (275/752, 36.5%) (p 0.09).
Susceptibility patterns of Candida spp. isolated from patients
with haematological malignancies
Of the 30 Candida isolates tested, eight (27%) were resistant to
at least one antifungal agent. For nine (30%) other isolates,
susceptibility was characterized as susceptible-dose dependent
(SDD) or intermediate to at least one antifungal agent.
Resistance was more common for itraconazole (four isolates
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were resistant and eight SDD). If itraconazole is excluded from
the analysis, then 17/30 (57%) isolates were susceptible to all
antifungal agents. Resistance to antifungal agents was observed
only among non-C. albicans species. Among the 13 available
isolates of C. parapsilosis, one was resistant and three had
intermediate susceptibility to at least one echinocandin, while
the remaining nine (69%) were susceptible to all echinocandins,
by using the most recent CLSI interpretive breakpoints [11].
Treatment
The most common treatment strategy after diagnosis of
candidaemia was initiation of antifungal therapy in patients not
receiving antifungal agents (45%) or switching to another class
of antifungals in cases of breakthrough infection (17.5%). Other
options included addition of antifungal agents to an existing
regimen (20%) and continuation of the initial antifungal therapy
(15%) (Table 2).
All CVCs were non-tunnelled and were inserted into the
subclavian vein. CVCs were removed within 3 days from the
onset of candidaemia in 11 patients (27.5%). Median duration
of treatment was 12 days (1–81 days) (Table 2). Follow-up
cultures were performed in 32 of 40 candidaemia cases.
Treatment resulted in negative blood cultures in 28 (86%) of
32 patients, with a median time period to negativity of 8 days
(range 1–20 days).
Outcome
Crude mortality in patients with candidaemia and haemato-
logical malignancies at day 28 was significantly higher (18
deaths, 45%) compared with control patients (9 deaths, 11%)
(p <0.0001) (Fig. 1). Early mortality was 17.5% at day 7 and
30% at day 14. Rates of clinical and mycological response to
antifungal therapy at day 7 following the index blood culture
for Candida were 35% and 47.5%, respectively. Overall
response (clinical and mycological) was 42.5% at day 14 and
55% at day 28.
TABLE 1. Demographics of the
study population and risk factors for
candidaemia in patients with hae-
matological malignancy
Characteristic
Case
patients
(n = 40)
Control
patients
(n = 80)
Unadjusted
OR (95% CI) Adjusted OR (95% CI)
Median age, years (range) 58 (19, 89) 55 (16, 89) 1.01 (0.99, 1.04)
Sex, n (%) 1.28 (0.6, 2.75)
Male 19 (48%) 43 (54%)
Female 21 (52%) 37 (46%)
Haematological malignancy, n (%) 1.17 (0.54, 1.26)
Leukaemia/myelodysplastic syndrome 24 (60%) 51 (64%)
Lymphoma/multiple myeloma 16 (40%) 29 (36%)
Surgical procedure (abdomen) 0 1 (1%) –
Diabetes mellitus 8 (20%) 10 (12%) 1.75 (0.63, 1.85)
Presence of CVC 31 (78%) 25 (31%) 7.58 (3.14, 18.27) 5.99 (2.36, 15.22)
TPN 2 (5%) 0
Hypogammaglobulinaemia, n (%) 20 (50%) 18 (23%) 3.39 (1.50, 7.64) 3.39 (1.35, 8.54)
Neutropenia, n (%) 29 (73%) 52 (65%) 1.42 (0.62, 3.26)
Profound neutropenia (<100/mL), n (%) 17 (59%) 28 (56%) 1.11 (0.44, 2.81)
Use of growth factors, n (%) 27 (68%) 48 (60%) 1.38 (0.62, 3.08)
Systemic corticosteroids within 4 weeks
before onset, n (%)
21 (52%) 35 (44%) 1.42 (0.66, 3.04)
Stem cell transplantation, n (%) 11 (28%) 19 (24%) 1.22 (0.51, 1.89)
Autologous 3 11
Allogeneic 8 8
Graft-vs.-host disease 3 2
APACHE II score at onset, n (%) 4.33 (1.62, 11.61) 3.06 (1.02, 9.20)
≥20 13 (33%) 8 (10%)
<20 27 (67%) 72 (90%)
Median APACHE II score (range) 17.5 (9, 32) 14 (4, 27)
OR, odds ratio; CVC, central venous catheter.
TABLE 2. Microbiology, treatment and outcome of patients
with Candidaemia and haematological malignancies
Microbiology and treatment parameter n = 40 cases
Causes of candidaemia
Organisms
Candida parapsilosis 20 (50%)
Candida tropicalis 6 (15%)
Candida albicans 5 (12.5%)
Candida glabrata 4 (10%)
Candida guilliermondii 2 (5%)
Other Candida speciesa 3 (7.5%)
Breakthrough candidaemiab 21 (53%)
CVC-related candidaemiab 20 (50%)
Treatment
Initiation of antifungal treatment in
patients not receiving antifungal agents
18 (45%)
Switching to another class of antifungals
in cases of breakthrough infection
7 (17.5%)
Addition of antifungal agents to the existing regimen 8 (20%)
Continuation of the initial antifungal therapy 6 (15%)
Removal of CVC (<72 h) 11 (27.5%)
Median duration of treatment (days, range) 12 (1–81)
Outcome
Clinical response (day 7) 14 (35%)
Mycological response (day 7) 19 (47.5%)
Overall response (day 28) 22 (55%)
Crude mortality (day 28) 18 (45%)
Susceptibility to antifungal agentsc
C. parapsilosis 11/13 (84.6%)
C. tropicalis 4/5 (80%)
C. albicans 4/4 (100%)
C. glabrata 2/4 (50%)
aCandida krusei, Candida dubliniensis, Candida kefyr.
bAccording to published definitions [Antoniadou et al.10]
cIsolates susceptible to all antifungal agents (excluding itraconazole). Data from 30
available isolates.
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Eleven of the 18 deaths that occurred among case patients
were characterized as Candida related. Five (45%) of these 11
deaths occurred by day 7 and seven (64%) were attributed to
septic shock. Among the Candida spp., C. glabrata was asso-
ciated with the highest crude mortality rate (4/4) at day 28,
while the lowest mortality was observed in C. parapsilosis (6/
20) (p 0.008).
Multivariate analysis showed that high APACHE II score (p
0.014; OR, 0.28 (95% CI, 0.06, 0.50)) was an independent risk
factor for 28-day mortality among case patients with candida-
emia, while neutrophil recovery was associated independently
with a favourable outcome [p 0.004; OR, 3.25 (95% CI,
5.74, 1.04)] (Table 3).
Discussion
To our knowledge, this is the first prospective, multicentre
study specifically designed to investigate the epidemiology, risk
factors and outcome of candidaemia among hospitalized
patients with haematological malignancies. We found that the
incidence of candidaemia was significantly higher among these
patients in comparison to non-haematology patients. Indepen-
dent risk factors for the development of candidaemia were the
presence of CVC, hypogammaglobulinaemia and high APACHE
II score. Most infections (87.5%) were due to non-C. albicans
species, with C. parapsilosis being the most common. Twen-
ty-eight-day crude mortality was 45%, with an elevated
APACHE II score being an independent risk factor for death;
however, recovery from neutropenia was independently
associated with improved survival.
The incidence of candidaemia during the 3-year study
period was 1.4 cases per 1000 admissions in haematology and/
or HSCT units. Although the incidence of candidaemia varies
greatly among different hospitals, countries and geographical
areas, similar incidences have been reported in European and
US studies [1,3,12]. In the 1980s, invasive candidiasis emerged
as the prominent mycosis in patients with haematological
malignancies. However, following widespread use of antifungal
triazole prophylaxis in the early 1990s in leukaemia units,
candidiasis has become less common [13]. There also has been
an expanded use of echinocandins for prevention and empirical
antifungal therapy of invasive candidiasis in neutropenic
patients, which may exert a selective microbiological effect
on C. parapsilosis in this population [14]. Despite these
preventive measures in patients with haematological malignan-
cies, we found that the incidence of candidaemia among
patients with haematological malignancies was significantly
higher compared with that of non-haematological adult
patients admitted during the study period. These data suggest
that haematological malignancy per se is a risk factor for
hospital-acquired candidaemia.
We found that hypogammaglobulinaemia was an indepen-
dent risk factor for development of candidaemia among
patients with haematological malignancies. Hypogammaglobu-
linaemia has not been reported previously as a risk factor for
candidaemia in haematological malignancies. This novel obser-
vation carries important implications for pathogenesis of the
disease, host defence mechanisms and immunotherapy.
Although polymorphonuclear leukocytes are the primary line
of innate host defence against deeply invasive Candida infec-
tions, the antibodies also have a key role in protection against
disseminated candidiasis. Pooled rabbit anti-Hyr1p polyclonal
antibodies raised against eight different peptide regions of
rHyr1p-N (C. albicans cell surface protein phagocyte killing
resistance factor) protected mice in a haematogenously
disseminated candidiasis model [15]. That antibodies specific
for C. albicans cell surface (1?2)-b-mannotriose [b-(Man)3]
protect mice from disseminated candidiasis [16] further
P < 0.0001
FIG. 1. Kaplan–Meier plot of survival in patients with haematological
malignancies and candidaemia vs. case controls with haematological
malignancies without candidaemia.
TABLE 3. Factors associated with crude mortality at day 28,
among 40 case patients
Variable
Bivariate
analysisa
Multivariate analysis
p value OR (95% CI) p value
Age >50 0.013 2.2 (0.74, 5.3) 0.14
Neutrophils <100/mL 1.0
APACHE II score 0.0001 0.28 (0.06, 0.50) 0.014
ECOG score 0.0003
Breakthrough infection 0.2
Neutrophil recovery 0.001 3.25 (5.47, 1.04) 0.004
Early (<72 h) CVC removal 0.073
New antifungal therapy 0.022
Intercurrent bacterial infection 0.31
Prior use of antibiotics 0.11
APACHE II, Acute Physiology and Chronic Health Evaluation II; ECOG, Eastern
Cooperative Oncology Group; CVC, central venous catheter.
aFisher’s exact test was used for categorical variables. The Wilcoxon rank-sum test
was used for continuous variables.
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supports the role of antibodies in host defence and possible
immunotherapeutics. The antibody titre threshold against the
N-terminus of the candidal adhesin, Als3p (rAls3p-N), predicts
anti-Candida vaccine efficacy in the prevention of disseminated
candidiasis, despite the mechanism of protection being induc-
tion of cell-mediated immunity [17]. Thus, hypogammaglobu-
linaemia in patients with haematological malignancies may be
an important biomarker for the risk of disseminated candidiasis
and further provide a rationale for vaccine therapy.
Another independent risk factor for the development of
candidaemia was an APACHE II score of ≥20. APACHE II
score has not been validated outside the ICU; however, it has
been used extensively in published candidaemia studies [18].
Previous studies have shown that increased APACHE II score
at the onset of candidaemia is a clinical predictor for
progression to septic shock [19] and is independently asso-
ciated with higher hospital mortality [18,20]. This finding
carries several important implications for patients with
haematological malignancies. First, sepsis syndrome and eleva-
tion of APACHE score may be the first manifestation of
candidaemia [19]. Second, rapid intervention with antifungal
therapy at this stage may be life-saving [21]. Third, candidaemia
also may be a surrogate marker of severe illness and
debilitation in patients with haematological malignancies.
Our study demonstrated a striking epidemiological preva-
lence of 87.5% non-C. albicans isolates among patients with
haematological malignancies and candidaemia. Whereas older
studies attributed such shifts towards non-C. albicans spp. to
widespread prophylactic use of fluconazole in haematology
units [22], in our study only 12/40 patients (30%) were
receiving a triazole at the onset of candidaemia. Recent studies
showed that in some centres a decline in fluconazole usage did
not influence the non-C. albicans spp. predominance [22] or
that fluconazole prophylaxis was not associated with a shift
towards non-C. albicans spp. [23]. Other factors, such as
broad-spectrum antibiotics and chemotherapy, might also
contribute to this trend [24]. We found that non-albicans
candidaemia was significantly more frequent in patients with
haematological malignancies compared with non-haematology
patients within the same hospital for the same time period.
This finding suggests that patients with haematological malig-
nancies have a distinct Candida epidemiology, not associated
with local epidemiology or hospital-associated factors.
The preponderance of C. parapsilosis in our study is distinct
from most reports of non-C. albicans spp. in patients with
haematological malignancies, in whom C. glabrata and Candida
krusei are most common. However, a retrospective study at the
M.D. Anderson Cancer Center showed that C. parapsilosis was
the most common species among patients with haematological
malignancies, during the period 2001–2007 [3]. The decline in
fluconazole or itraconazole usage in favour of echinocandins
and voriconazole as prophylactic agents may have contributed
to this epidemiological change. Echinocandins have elevated
MICs against C. parapsilosis, which may be correlated with
refractory candidaemia or breakthrough infections [25]. Other
Candida spp., including C. glabrata, C. tropicalis and C. krusei, also
may emerge as resistant isolates during echinocandin therapy
[26,27]. A recent study showed significant correlation between
increased caspofungin usage and increased incidence of C. par-
apsilosis candidaemia [28]. In our study, only two case patients
were receiving an echinocandin at the onset of candidaemia.
The prevalence of non-C. albicans species, especially C. parapsi-
losis, despite the low percentage of patients receiving prophy-
laxis suggests that the prior use of antifungal agents is not the
only driving force in the shift in distribution of Candida species
among patients with haematological malignancies. The 2009
IDSA guidelines recommend empirical treatment of neutrope-
nic patients with suspected candidaemia [29]. However, as
observed in this study, breakthrough candidaemia with C. par-
apsilosis may develop during neutropenia, possibly in relation to
the high MICs of echinocandins.
Our study introduces an important observation of a
relatively high proportion (50%) of CVC-related candidaemia
episodes. That C. parapsilosis, which is strongly associated with
vascular catheter infections, also was found in this same
cohort, suggests an evolution of candidaemia toward CVCs as
a portal of entry. In previous studies, CVCs were considered
to be uncommon sources of breakthrough fungaemia in
haematological malignancy patients, with the understanding
that the alimentary tract was the principal portal of entry for
candidaemia in neutropenic hosts [30]. However, C. parapsi-
losis is known to adhere to the surface of CVCs through
biofilm formation and thus cause candidaemia [31]. Identifica-
tion of CVCs as an independent risk factor for the develop-
ment of candidaemia further substantiates their relationship
with C. parapsilosis as an emerging pathogen in patients with
haematological malignancies.
The high rate of C. parapsilosis candidaemia and CVC-re-
lated infections might suggest poor hand hygiene standards of
healthcare workers because C. parapsilosis is a common skin
saprophyte [32]. Yet, in the non-haematology patients of our
study, treated in the same hospitals for the same time period,
the frequency of C. parapsilosis was lower. If we take into
consideration that hand hygiene policies are usually stricter in
haematology units, and that C. parapsilosis also was the
predominant Candida species among haematology patients in
a USA-based hospital [3], then transmission of C. parapsilosis
by the personnel is a less rational explanation. One may
hypothesize that C. parapsilosis in some patients with
haematological malignancies may originate from their own
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O50–O57
CMI Gamaletsou et al. Candidaemia in patients with haematological malignancies O55
endogenous cutaneous biome in the setting of expanded use of
echinocandins.
We found that among patients with haematological malig-
nancies and candidaemia the overall mortality at day 28 was
45%, and the Candida-related mortality was 27.5%. Crude
mortality was significantly higher compared with controls (45%
vs. 11%, p <0.001; excess mortality, 34%). Similarly high crude
and attributable mortality rates among patients with haema-
tological malignancies have been reported in previous retro-
spective studies from Europe and the USA [2,3,33]. The poor
outcome of our study patients, along with the poor clinical and
mycological response to antifungal therapy at day 7 (35% and
47.5%, respectively), suggests that candidaemia in patients with
haematological malignancies is an ominous sign irrespective of
antifungal treatment.
This study had limitations. Our data do not exclude the
possibility that the observed incidence of candidaemia is an
underestimation of the real incidence because autopsies were
not performed in the participating centres. Despite important
technological advances in blood cultures [34], post-mortem
studies demonstrate that they remain insensitive in detecting
ante-mortem deep tissue candidiasis, especially among patients
with haematological malignancies who were receiving antifungal
prophylaxis [35]. Secondly, we had a limited absolute number of
case patients, due to the relatively low incidence of candida-
emia, which did not allow assessment of other potentially
important parameters for candidaemia or candidaemia-related
mortality. Finally, only Greek hospitals participated in the study;
therefore, generalization of our findings to other geographical
areas may not be feasible. On the other hand, to our knowledge
this is the first multicentre, prospective study on candidaemia
among patients with haematological malignancies, without the
shortcomings of retrospective, single-centre studies.
In conclusion, this multicentre, prospective study showed
that the epidemiology of candidaemia in high-risk patients with
haematological malignancies is a continually evolving challenge
with regard to successful outcome. Our study adds CVC and
hypogammaglobulinaemia as new independent risk factors for
candidaemia in patients with haematological malignancies. We
found a predominance of non-C. albicans isolates, especially
C. parapsilosis, frequently resistant to at least one antifungal
agent. Therefore, defining the optimal management in this
high-risk patient population, which typically is not included in
candidaemia trials, still remains a major challenge.
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